On April 24, 2025, Aspire Biopharma Holdings, Inc. resolved default notices with lenders, extending loan maturity dates and issuing 625,000 shares as part of the settlement, enhancing operational flexibility. The lenders canceled previous defaults, affirming a strengthened relationship with Aspire.